-
Article
Open AccessCombination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
-
Article
Open AccessTargeting hematologic malignancies with oncolytic vaccinia virus constructs
-
Article
Open AccessThe highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation
As a new anticancer treatment option, vaccinia virus (VACV) has shown remarkable antitumor activities (oncolysis) in preclinical studies, but potential infection of other organs remains a safety concern. We pr...
-
Article
Open AccessSystemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy
GLV-1h68 is an attenuated recombinant vaccinia virus (VACV) that selectively colonizes established human xenografts inducing their complete regression.
-
Article
Open AccessOncolytic vaccinia therapy of squamous cell carcinoma
Novel therapies are necessary to improve outcomes for patients with squamous cell carcinomas (SCC) of the head and neck. Historically, vaccinia virus was administered widely to humans as a vaccine and led to t...
-
Article
Open AccessA Novel Recombinant Vaccinia Virus Expressing the Human Norepinephrine Transporter Retains Oncolytic Potential and Facilitates Deep-Tissue Imaging
Noninvasive and repetitive monitoring of a virus in target tissues and/or specific organs of the body is highly desirable for the development of safe and efficient cancer virotherapeutics. We have previously s...
-
Article
Open AccessGenomic sequence and analysis of a vaccinia virus isolate from a patient with a smallpox vaccine-related complication
Vaccinia virus (VACV)-DUKE was isolated from a lesion on a 54 year old female who presented to a doctor at the Duke University Medical Center. She was diagnosed with progressive vaccinia and treated with vacci...
